Percutaneous Coronary Intervention (PCI) Devices Market Size, Share, Trends, & Industry Analysis Report
: By Product (Coronary Catheters, Coronary Guidewires, Coronary Stents, and Accessories), By End Use, By Regions -Market Forecast, 2025 –2034
- Published Date:Sep-2025
- Pages: 107
- Format: PDF
- Report ID: PM1695
- Base Year: 2024
- Historical Data: 2020-2023
What is the global percutaneous coronary intervention (PCI) devices market size?
The global percutaneous coronary intervention (PCI) devices market size was valued at USD 9.50 billion in 2024 and is anticipated to grow at a CAGR of 5.68% from 2025 to 2034. Key factors driving demand for percutaneous coronary intervention (PCI) devices include rising prevalence of cardiovascular diseases (CVDs), increasing aging and obese populations, and favorable regulatory support.
Key Insights
- The coronary stent segment accounted for a major revenue share in 2024 due to its high usage in heart-related procedures.
- In 2024, the hospital segment held the largest revenue share, owing to the higher patient admissions.
- The North America region held the largest revenue share in 2024 due to the rising incidence of heart diseases.
- Asia Pacific is projected to grow at the fastest rate in the coming years, owing to technological advancements.
Industry Dynamics
- The increase in the number of cases of coronary artery diseases is propelling the market growth.
- The increase in the obese and geriatric populations across the globe is fueling the demand for percutaneous coronary intervention (PCI) devices.
- The rise in chronic conditions globally is creating a lucrative market opportunity.
- The high cost of percutaneous coronary intervention (PCI) devices may hamper the market growth.
Market Statistics
- 2024 Market Size: USD 9.50 Billion
- 2034 Projected Market Size: USD 16.47 Billion
- CAGR (2025-2034): 5.68%
- North America: Largest Market Share
-devices-size-by-region-2020-2034.webp)
To Understand More About this Research: Request a Free Sample Report
AI Impact on Percutaneous Coronary Intervention (PCI) Devices Market
- AI helps in improving the detection of coronary blockages.
- AI guides stent selection and placement strategies.
- AI reduces procedure time through real-time guidance.
The growth of the market is attributed to the increasing technological advances, new product launches, unhealthy lifestyle habits, and high prevalence of coronary artery disease (CAD). A rapid shift towards MI techniques such as PCI procedures, which are used to treat CAD conditions, is significantly gaining prominence amongphysicians. Also, an increase in the obese and geriatric population positively drives the market, as they are most prone to cardiac diseases. Adding to the high-risk factors also includes diabetes and sedentary lifestyle habits, which increase the PCI procedures. As they cause heart disease, stroke, and many other complications.
Industry Dynamics
Growth Drivers
Coronary artery disease is the most common heart disease, affecting millions of people globally. Coronary artery disease (CAD) is usually caused by the development of the plaque on the walls of the arteries that carry blood to the heart (coronary arteries). It blocks the carrying blood vessel, which results in unevenness in blood flow through partial narrowing of those arteries, also known as atherosclerosis. The incidence of CAD in high-income countries is increased due to faulty lifestyles, high-fat diets, excessive consumption of alcohol, and smoking.
-devices-market-size-worth-usd-16.47-billion-by-2034.webp)
Know more about this report: request for sample pages
The acute coronary syndrome includes unstable angina and heart attack. Angina, which is the major symptom of the CAD includes chest pain and discomfort. As per CDC estimation of 2.7 to 6.1 million people in the U.S. have atrial fibrillation (AFib). More than 750,000 hospitalizations occur each year and contribute to an estimated death toll of 130,000 each year.
Globally, millions of people have one or more risk factors for the heart disease, such as high blood pressure smoking and high cholesterol. For instance, according to CDC about 30.3 million in the US have diabetes; that is 9.4% of the US population. Such a drastic number of diseased populations could potentially fuel the use of PCI procedures which are used to treat the CAD.
Also, coronary heart disease forms the second leading cause of cardiovascular deaths in the Chinese population, accounting for 23% of deaths in urban areas and 14% of deaths in rural areas. There are approximately 3 million deaths due to CVD every year, accounting for 41 per cent of the total deaths in China.
Also, about 2.4 million people in Canada aged 20 years above live with ischemic heart disease. Heart diseases stand in second place in Canada, claiming more than 48500 lives in 2012. Also, every 7 minutes CVD kills one person in Canada. Likewise, in the European region CVD causes more than half of the deaths. The disease burden of CVD in the European region is more than AIDS, tuberculosis, and malaria combined. Factors such as globalization, urbanizations, diabetes, alcohol, tobacco, and inactivity contribute to the growing number of CAD diseases. Thus, increasing the incidence of coronary heart diseases increases the adoption of PCI procedures thus fueling the percutaneous coronary intervention devices market.
Challenges
The global market is hindered by the few side effects associated with coronary intervention devices and accessories. The common challenges that occurred during the procedure include allergies to local anesthesia, adverse reactions to the contrast media in use, and complications during cardiac catheterization. During cardiac catheterization, the possible complications are bleeding, infection, and pain at the insertion site. Further potential damage might occur when the catheter pokes a hole in the blood vessels.
What is the emerging trend in the percutaneous coronary intervention (PCI) devices market?
Robotic-assisted percutaneous coronary intervention (R-PCI) is expected to become a key industry trend in the coming years. In this practice, robots are used to perform interventions remotely. The robotic system setup consists of two major components—cockpit and robotic arm. R-PCI devices offer various benefits, including reduced radiation exposure, enhanced ergonomics, improved precision, and potential for tele-stenting. Rising integration of AI, machine learning, and advanced imaging systems is expected to boost developments in these devices. However, high costs and technology constraints are hindering the adoption of these systems. Following table provides detailed information of players providing R-PCI devices with their activities and recent developments.
|
Company |
Product/Platform |
Key Activities & Focus Areas |
Recent Developments |
|
Corindus (Siemens Healthineers) |
CorPath GRX/GRX Plus |
|
|
|
Robocath |
RAS (Robotic Angioplasty System) |
|
|
|
Stereotaxis |
Niobe ES |
|
|
|
Medtronic |
Hugo Robotic System |
|
|
|
Intuitive Surgical |
da Vinci Surgical System |
|
|
|
Auris Health (Johnson & Johnson) |
Monarch Platform |
|
|
|
Philips Healthcare |
Azurion with FlexArm |
|
|
|
Boston Scientific |
- |
|
|
Percutaneous Coronary Intervention Devices Market Report Scope
The market is primarily segmented on the basis of product, by end use, and by geographic region.
|
By Product |
By End Use |
By Region |
|
|
|
Know more about this report: request for sample pages
Insight by Product
Based upon product, the global PCI devices market is categorized into coronary catheters, coronary guidewires, coronary stents, and accessories. The coronary stent segment accounted for the majority of the share in 2024. The factors responsible for its high share are its high usage in heart-related procedures, consumer preference towards minimally invasive surgeries, and technological advancements in the product category. The segment is expected to remain dominant over the study period, owing to continuous innovation in the product by the manufacturers possessing efficient clinical outcomes.
-devices-by-product-analysis-2020-2034.webp)
Insight by End Use
On the basis of end use, the global market is categorized into hospitals, catheterization labs, and ambulatory surgical centers. In 2024, the hospital segment held the largest share, owing to the higher patient admissions coming for the surgical procedures. These hospitals have advanced technologies supporting MI procedures, trained professionals, and advanced robotic devices performing PCI techniques. Moreover, hospitals are equipped with advanced diagnostic and therapeutic systems, which help in accurate diagnosis and treatment of the disease. Tie-ups with reimbursement authorities such as Medicare and Medicaid policies, regulatory authorities, and the constant pressure of reducing cost by the Affordable Care Act (ACT) increase the utilization of the hospitals.
Geographic Overview
Geographically, the global PCI devices market is bifurcated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). North America region is the largest revenue contributor, followed by Europe and the Asia Pacific regions. In 2024, the North America region accounted for more than 34.23% of the global market. The US and Canada were the major revenue contributors. According to CDC statistics, one out of four deaths in the U.S. is due to heart diseases. Physicians are performing approximately 300,000 balloon angioplasty procedures annually in the US. Unhealthy habits, high elevated blood pressure with cholesterol increase the risk of heart attacks/stroke. CDC states that in every 40 seconds someone in the US suffers with heart attack. This high incidence rate of CAD fuels the demand for percutaneous coronary intervention devices in the Americas market.
The growth of the market in the region is also influenced by the growing number of technological advancements, with players focusing on R&D to design novel products that cater to the requirements of the physicians. The increasing number of Food and Drug Administration (FDA) approvals and the launch of third-generation stents significantly impact the market, as the new generation stents proven to show fewer side effects and improved clinical outcomes with less chance of restenosis.
Japan, India, South Korea, and China are the top three revenue generators in the APAC regions. With the high incidence of CAD, the increased volume of PCI procedures coupled with contributing factors such as diabetes, obesity, and sedentary lifestyles spurs the market growth. Also, increased awareness of MI PCI procedures in these countries significantly contributing to the market growth. With the rapid urbanization of many developing countries in the region and the increase in the disposable income of the people lead to change in lifestyles, such as smoking, excessive alcohol use, and unhealthy habits, have increased the risk of CAD. This is propelling the market growth.
-devices-trends-by-region-2020-2034.webp)
Competitive Insight
The percutaneous coronary intervention (PCI) devices market shows strong competition. This is due to a rise in cardiovascular cases, and healthcare systems emphasize minimally invasive treatments. The increase in use of drug-eluting stents, improved balloon technologies, and advanced catheters is propelling the competition. Companies in the industry are investing in product innovation to broaden their reach. The landscape is further influenced by ongoing improvements in imaging and navigation tools. The market is projected to remain highly dynamic, as hospitals and clinics increase adoption of PCI procedures.
Key players in the market are Abbott, B. Braun, ASAHI INTECC Company Limited, Biosensors International Group, Ltd, Boston Scientific Corporation, C. R. Bard, BIOTRONIK, Comed BV, Cook, Meril Lifesciences, Cordis, Medtronic PLC, Merit Medical System, and Terumo Corporation.
Industry Developments
May 2024, Abbott, the global healthcare company, announced the launch of XIENCE Sierra Everolimus (drug) eluting coronary stent system in India.
Percutaneous Coronary Intervention (PCI) Devices Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 9.50 Billion |
|
Market Size in 2025 |
USD 10.02 Billion |
|
Revenue Forecast by 2034 |
USD 16.47 Billion |
|
CAGR |
5.68% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
• The global market size was valued at USD 9.50 billion in 2024 and is projected to grow to USD 16.47 billion by 2034.
• The global market is projected to register a CAGR of 5.68% during the forecast period.
• North America dominated the market in 2024.
• A few of the key players in the market are Abbott, B. Braun, ASAHI INTECC Company Limited, Biosensors International Group, Ltd, Boston Scientific Corporation, C. R. Bard, BIOTRONIK, Comed BV, Cook, Meril Lifesciences, Cordis, Medtronic PLC, Merit Medical System, and Terumo Corporation.
• The coronary stent segment dominated the market revenue share in 2024.
© 2025 Polaris Market Research and Consulting. All rights reserved
